Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?Drugpatentwatch market analysis industry today?Brenzavvy discontinuation?How does paclitaxel's binding to albumin change its pharmacokinetics?What are the most memorable drug brands in oral factor b inhibitors? in united states
See the DrugPatentWatch profile for gefitinib
Gefitinib is marketed as the branded cancer medicine Iressa. [1] The generic name is also gefitinib. [1] There is no separate, widely used “ingredient name” distinct from the generic here because gefitinib itself is the active ingredient. [1] A chemical/descriptor name commonly used for gefitinib is: - 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(morpholin-4-yl)quinazoline (This is the core chemical name used to define gefitinib’s structure.) [2] SU011248 is a code/identifier associated with gefitinib development rather than a separate marketed generic/brand. [3]
Drug records often contain several different “name types” for the same medicine: - Brand name (what patients see on prescriptions), such as Iressa. [1] - Generic name (the drug substance name), such as gefitinib. [1] - Chemical name (structure-based naming used in chemistry/databases), such as the quinazoline derivative chemical name listed above. [2] - Development code/name (often used in early research and filings), such as SU011248 for gefitinib. [3]
For gefitinib, the ingredient is the active drug substance itself: gefitinib. [1] So the “ingredient name” and the “generic name” point to the same entity in typical drug references. [1]